Following the previous discussions on IoT in Cryo-EM and the resurgence of the manual plunge...
For May 2023, we're spotlighting the Glucagon-Like Peptide-2 Receptor (GLP2R) as the 'Clovertex Drug Target of the Month'. GLP2R plays a vital role in intestinal growth and function, and is notably targeted by apraglutide, a promising drug developed by VectivBio.
Apraglutide, currently in Phase III trials, shows significant potential in transforming the treatment outlook for Short Bowel Syndrome with Intestinal Failure (SBS-IF), and acute Graft versus Host Disease (aGVHD) in those who have undergone allogeneic hemopoetic stem cell transplantation.
In a significant development, VectivBio has entered an acquisition agreement with Ironwood Pharmaceuticals, an all-cash deal valued at $1 billion. This strategic move underscores the growing importance of GLP2R in therapeutic development.
The protein model rendering features the cryo-EM structure of the GLP2R-Gs complex (PDB 7D68) and we look forward to the progress this deal promises, specifically for apraglutide and the further exploration of GLP2R targeted therapies.
About Clovertex
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
Useful links
1. VectivBio taken over in $1bn acquisition
2. Clovertex website
